Exubera news from FiercePharma
NewsSPOTLIGHT: Ex-Exubera plant to shut down
Pfizer will shutter its sterile manufacturing plant in Terre Haute--where the now-defunct inhaled insulin product Exubera was made--by mid-2009, eliminating the facility's remaining 140 jobs. More Read more...
What Exubera says about safety
When Pfizer announced yesterday that the inhaled insulin product it spiked last fall may have triggered lung cancer in a few patients, pundits immediately pronounced the death of all insulin Read more...
Pfizer cuts 660 at Exubera plant
Workers at Pfizer's Terre Haute, Indiana, plant where the ill-fated Exubera was made are, shall we say, less than exuberant today. The company has decided to cut 660 jobs there; after all, it's not Read more...
ALSO NOTED: Regulators reconsider Ransom recall; Consort profits plummet on Exubera loss
> Whew! That's the mood at U.K. pharma William Ransom as regulators dialed back their Read more...
Pfizer pays $135M to ease Exubera pain
Exubera fallout alert: Pfizer has reached a deal with its partner on the drug, Nektar Therapeutics. The Read more...
Pfizer kills off Exubera, hunts for deals
It's official: Pfizer is giving up on Exubera. Pulling its plug cost the company $2.8 Read more...
Pfizer honcho details plans to boost sales
Pfizer's drug chief opened up his playbook yesterday at a San Francisco investment conference. Ian Read, president of worldwide pharmaceutical operations, confided worries about its top seller, Read more...
SPOTLIGHT: Exubera pain grows worse
The pain of dismal Exubera sales is spreading. West Pharmaceutical Services, which makes Read more...
| Press ReleasesPRESS RELEASE: Pfizer and Nektar Reach Agreement on Exubera Pfizer and Nektar Reach Agreement on Exubera NEW YORK & SAN CARLOS, Calif. -- Pfizer and Nektar Therapeutics announced today that the two companies have resolved all outstanding contractual Read more... PRESS RELEASE (EXCERPT): Pfizer returns Exubera rights Pfizer Inc posted third-quarter 2007 revenues of $12.0 billion, a 2% decline from the same period last year. The Company’s reported net income was $761 million in the third quarter of 2007, a Read more... |
Get more Exubera coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets